BRAFTOVI Hard capsule (2019)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Braftovi 50 mg hard capsules. Braftovi 75 mg hard capsules.
Qualitative and quantitative composition
Braftovi 50 mg hard capsules: Each hard capsule contains 50 mg of encorafenib. Braftovi 75 mg hard capsules: Each hard capsule contains 75 mg of encorafenib. For the full list of excipients, see section ...
Pharmaceutical form
Hard capsule (capsule). Braftovi 50 mg hard capsules: Orange opaque cap and flesh opaque body, printed with a stylised A on the cap and LGX 50mg on the body. The length of the capsule is approximately ...
Therapeutic indications
Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1).
Posology and method of administration
Encorafenib treatment in combination with binimetinib should be initiated and supervised under the responsibility of a physician experienced in the use of anticancer medicinal products. Posology The recommended ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Special warnings and precautions for use
Encorafenib is to be given in combination with binimetinib. For additional information on warnings and precautions associated with binimetinib treatment, see section 4.4 of binimetinib SmPC. BRAF mutation ...
Interaction with other medicinal products and other forms of interaction
Effects of other medicinal products on encorafenib Encorafenib is primarily metabolised by CYP3A4. CYP3A4 inhibitors Co-administration of moderate (diltiazem) and strong (posaconazole) CYP3A4 inhibitors ...
Fertility, pregnancy and lactation
Women of childbearing potential/Contraception in females Women of childbearing potential must use effective contraception during treatment with encorafenib and for at least 1 month following the last dose. ...
Effects on ability to drive and use machines
Encorafenib has minor influence on the ability to drive or use machines. Visual disturbances have been reported in some patients treated with encorafenib during clinical studies. Patients should be advised ...
Undesirable effects
Summary of safety profile The safety of encorafenib (450 mg orally once daily) in combination with binimetinib (45 mg orally twice daily) was evaluated in 274 patients with BRAF V600 mutant unresectable ...
Overdose
Symptoms At doses of encorafenib between 600 to 800 mg once daily, renal dysfunction (Grade 3 hypercreatinaemia) was observed in 3 out of 14 patients. The highest administered dose occurred as a dosing ...
Pharmacodynamic properties
Pharmacotherapeutic group: antineoplastic agent, protein kinase inhibitor ATC code: L01XE46 Mechanism of action Encorafenib is a potent and highly selective ATP-competitive small molecule RAF kinase inhibitor. ...
Pharmacokinetic properties
The pharmacokinetics of encorafenib were studied in healthy subjects and patients with solid tumours, including advanced and unresectable or metastatic cutaneous melanoma harbouring a BRAF-V600E or K mutation. ...
Preclinical safety data
In the 4-week and 13-week rat toxicity studies, clinical signs, reduced body weight reduced epididymides and prostate weights and microscopic findings in testes, epididymides, stomach and skin were noted. ...
List of excipients
Capsule content: Copovidone (E1208) Poloxamer 188 Cellulose microcrystalline (E460i) Succinic acid (E363) Crospovidone (E1202) Silica colloidal anhydrous (E551) Magnesium stearate (E470b) Capsule shell: ...
Incompatibilities
Not applicable.
Shelf life
Shelf life: 3 years.
Special precautions for storage
Store below 30°C. Store in the original package in order to protect from moisture.
Nature and contents of container
Braftovi 50 mg hard capsules: Polyamide/aluminum/PVC/aluminum blister containing 4 capsules. Each pack contains either 28 or 112 hard capsules. Not all pack sizes may be marketed. Braftovi 75 mg hard capsules: ...
Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Marketing authorization holder
Pierre Fabre Médicament, 45, place Abel Gance, 92100, Boulogne-Billancourt, France
Marketing authorization number(s)
Braftovi 50 mg hard capsules: EU/1/18/1314/001 28 hard capsules EU/1/18/1314/003 112 hard capsules Braftovi 75 mg hard capsules: EU/1/18/1314/002 42 hard capsules EU/1/18/1314/004 168 hard capsules
Date of first authorization / renewal of the authorization
Date of first authorisation: 20 September 2018
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: